The Certified MAT Advocacy (CMA) Training, offered by the National Alliance for Medication Assisted Recovery (NAMA Recovery), is an intensive and empowering program that certifies participants to become Certified MAT Advocates (CMAs)—peer leaders trained to advocate for individuals receiving medications for opioid use disorder (MOUD), including methadone, buprenorphine, and naltrexone. This training is deeply rooted…
Read more
Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first opioid treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association (now AATOD) and as Vice Chair of…
Read more
Congratulations to the 2024 Richard Lane/Robert Holden Patient Advocacy Award winner, Anita R. Kennedy from New York, NY. The award was given at the 2024 AATOD Conference in Las Vegas. Be on the lookout for details about the 2025 Richard Lane/Robert Holden Patient Advocacy Award Nominations. This award will be given during the 2025 AATOD…
Read more
FOR IMMEDIATE RELEASE March 8, 2023 The bipartisan, bicameral legislation would expand access to methadone for the treatment of opioid use disorder Rockville, MD – The American Society of Addiction Medicine (ASAM) and the National Alliance for Medication Assisted Recovery (NAMA Recovery) today applauded Senators Edward Markey (MA) and Rand Paul (KY) and Representatives Donald Norcross…
Read more
The federal regulations in 42 CFR Part 8 (that oversee the use of buprenorphine and methadone in opioid treatment programs/”methadone clinics”) are being revised! There is a Notice of Proposed Rulemaking (NPRM) currently open in the federal register where organizations and individuals may leave public comments on the proposed new rules. Overall, the proposed revisions…
Read more
HIPAA is not good enough for criminalized and stigmatized health information, such as records related to substance use disorder (SUD) care! Aligning 42 CFR Part 2 (the federal regulations governing SUD treatment records) with HIPAA will not only discourage people from entering life-saving addiction treatment, but it will also put patients at risk of arrest, prosecution, incarceration, and discrimination based on their past substance use.
The 2022 Richard Lane/Robert Holden Patient Advocacy Award was presented at an Awards Reception held in conjunction with the 2022 Conference of the American Association for the Treatment of Opioid Dependence (AATOD) in Baltimore, Maryland on November 2, 2022. Richard Lane/Robert Holden Patient Advocacy Award Richard Lane was a long-term heroin user who, upon release…
Read more
The 2022 Certified MAT Advocacy (CMA) training course will be held on October 20, 2022, in Baltimore!
Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first opioid treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association (now AATOD) and as Vice Chairman of…
Read more
“The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (ADA), which prohibits discrimination against people in recovery from opioid use disorder (OUD) who are not engaging in…
Read more
Recent Comments